Adderall vs Ritalin for adults: amphetamine or methylphenidate

Adderall and Ritalin are the most familiar names in the two stimulant families used for ADHD. Adderall is an amphetamine product, and Ritalin is methylphenidate. Both are FDA-approved for ADHD in adults in at least one form, both are Schedule II controlled substances, and both carry the same boxed warning about abuse, misuse and addiction. The differences lie in the molecule, the forms each brand comes in, and some label warnings. This comparison uses the current FDA labels and the largest network meta-analysis of adult trials, as of October 2026.

Each brand name covers more than one product. Adderall means immediate-release (IR) tablets or Adderall XR capsules. Ritalin means immediate-release tablets, while Ritalin LA capsules are a separate product labeled only for children. The broader question of the two families is covered in methylphenidate vs amphetamine.

Side by side

How they work, in plain words

Both are central nervous system stimulants. Neither label claims to know exactly how the drug improves ADHD: the Ritalin label says the "mode of therapeutic action in ADHD and narcolepsy is not known," and the amphetamine labels say much the same. Because the two molecules are different, a person can respond differently to each, which is why guidelines such as NICE suggest trying the other family if the first does not help enough.

What the research says in adults

Most direct comparisons are at the family level (amphetamines vs methylphenidate), not brand vs brand.

• Efficacy. In the 2018 Lancet Psychiatry network meta-analysis by Cortese and colleagues (133 double-blind trials), both amphetamines and methylphenidate reduced clinician-rated adult ADHD symptoms more than placebo at about 12 weeks. In head-to-head comparisons in adults, amphetamines showed a larger effect than methylphenidate on clinician ratings.
• Tolerability. In adults, both amphetamines and methylphenidate were less well tolerated than placebo, measured by people leaving trials because of side effects.
• The authors' own conclusion. Weighing efficacy and safety, they wrote that the evidence "supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD." They also found too little data at 26 and 52 weeks to say anything about longer use.
• A different guideline view. The UK NICE guideline recommends lisdexamfetamine or methylphenidate as first-line options for adults, and suggests switching to the other if a six-week trial of one does not give enough benefit.

Taken together: on average, amphetamines showed somewhat larger short-term effects in adult trials, methylphenidate remains a standard first-line choice in major guidelines, and individual response varies. Neither is better for every adult. More on reading these numbers is in does ADHD treatment work in adults?

Practical differences

• Schedule through the day. Ritalin tablets and Adderall IR are both short-acting. The Ritalin label suggests that people who cannot sleep when they take it late in the day take the last dose before 6 p.m. Long-acting forms exist in both families: Adderall XR for amphetamine and products such as Concerta for methylphenidate.
• Eye and other warnings. Methylphenidate labels list acute angle-closure glaucoma, increased eye pressure and priapism among their warnings. People with glaucoma or a history of it should raise this before starting.
• Interactions. Amphetamine labels warn that alkalinizing agents raise blood levels and acidifying agents lower them. Both families are contraindicated with MAOIs or within 14 days of stopping one, and both labels list serotonin syndrome risk with some serotonergic drugs.
• Supply. As of October 19, 2026, the FDA shortage database lists mixed amphetamine salts IR tablets and methylphenidate extended-release tablets as current shortages. Methylphenidate IR tablets did not appear as a current shortage in that check.

The drug pages for Adderall and Ritalin have more detail from each label, and side effects of ADHD medication in adults explains which effects call for a call to the prescriber.

New York and New Jersey rules that apply to both

Both medications on this page are Schedule II controlled substances, so the same prescription rules apply to either one. In New York, a Schedule II prescription cannot be refilled; when more medication is needed, the prescriber issues a new prescription (10 NYCRR 80.67). New Jersey's controlled dangerous substance rules also bar refills of Schedule II prescriptions (N.J.A.C. 13:45H-7.9). Supply limits, the 30-day window to fill, electronic prescribing and the monitoring-program checks are covered in New York's rules for ADHD stimulant prescriptions and New Jersey's rules for ADHD stimulant prescriptions. Switching from one stimulant to another does not change any of these rules.

Questions worth asking

• Does my history of response to either family (including in childhood) point one way?
• Do I need a short-acting option for parts of the day, a long-acting one, or both?
• Do I have glaucoma, heart disease or high blood pressure that changes the choice?
• Which of my other medicines interact with either one?
• If one does not help enough, what is the plan for trying the other?

Talking it through with a prescriber

Dr. Shershow is a psychiatrist who focuses on adult ADHD and is licensed in New York and New Jersey. After an adult ADHD evaluation, he discusses the treatment options that fit, including medication when it is appropriate, and follows up over time. The comparison above is general information from FDA labels and published research. It is not advice to start, stop or switch any medication, and neither drug is the right choice for everyone.